Sex-related differences in the short and long-term outcome of internal pallidus stimulation for dystonia
Magnetic Resonance–Guided Focused Ultrasound Thalamotomy in a Prospective Cohort of 52 Patients with Parkinson's Disease: A Possible Critical Role of Age and Lesion Volume for Predicting Tremor Relapse
Early thinking palliative care for people with Parkinson's disease: A thematic synthesis based on a systematic mixed-methods review
Long-Term Motor and Cognitive Outcome of Deep Brain Stimulation in Patients With Parkinson Disease With a <i>GBA1</i> Pathogenic Variant
Effects of a Four‐Strain Probiotic on Gut Microbiota, Inflammation, and Symptoms in Parkinson's Disease: A Randomized Clinical Trial
Effects of <i>GBA1</i> Variants in Patients With Parkinson's Disease and Levodopa–Carbidopa Intestinal Gel: A Nation‐Wide, Multicenter, Longitudinal, “Real‐World” Study. The <scp>EPIC</scp> Study
Unraveling the role of GBA1 genotype in axial signs response to subthalamic deep brain stimulation
Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson’s disease
Aceruloplasminemia: Unique Clinical and <scp>MRI</scp> Findings in a Patient with a Novel Frameshift Mutation
Causative Role of the <scp><i>SLC6A1</i></scp> p.<scp>Asp451Gly</scp> Variant in a Patient with Combined Dystonia and Neurodevelopmental Disorder
Reply to: “Heterogeneous Phenotypic Evolution in <scp><i>ANO3</i></scp>‐Related Dystonia Due to the Recurrent p.<scp>Glu510Lys</scp> Variant”
Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice
Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in <i>GBA</i>-associated Parkinson’s disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol
<scp><i>ANO3</i></scp> as a Cause of Early‐Onset Chorea Combined with Dystonia: Illustration of Phenotypic Evolution
Viruses, parkinsonism and Parkinson’s disease: the past, present and future
Covid-19 and Parkinson's disease: Acute clinical implications, long-COVID and post-COVID-19 parkinsonism
Gastrointestinal dysfunction in Parkinson’s disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation
Parkinson's Disease and <scp>Post–COVID</scp>‐19 Syndrome: The Parkinson's <scp>Long‐COVID</scp> Spectrum
Neurogenic and anti-inflammatory effects of probiotics in Parkinson’s disease: A systematic review of preclinical and clinical evidence
Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease
Cross-sectional analysis of the Parkinson’s disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life
Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience
Personalised Advanced Therapies in Parkinson’s Disease: The Role of Non-Motor Symptoms Profile
Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease
Outcome of Parkinson's Disease Patients Affected by <scp>COVID</scp>‐19
COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside
Drooling in Parkinson’s Disease: Prevalence and Progression from the Non-motor International Longitudinal Study
Identifying and responding to fatigue and apathy in Parkinson’s disease: a review of current practice
Serum Uric Acid Levels and Non-Motor Symptoms in Parkinson’s Disease